TITLE

Clinical Trials Headed For IPOs, M&A

AUTHOR(S)
Abrams, Sandra Lea
PUB. DATE
February 2005
SOURCE
Investment Dealers' Digest;2/21/2005, Vol. 71 Issue 7, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the trend of increasing outsourcing of clinical trials by drug companies. As pharmaceutical, biotechnology and generic drug companies outsource more of their clinical trial testing to contract research organizations (CRO), these CROs are turning to the capital markets to raise money. The boomlet is also leading to mergers in this $9 billion market, which is expected to have 8.5% annual growth over the next five years. The most recent CRO to go public, PRA International Inc., debuted in November, raising $68.4 million with CSFB as lead manager.
ACCESSION #
16201946

 

Related Articles

  • The changing landscape of clinical trial outsourcing. Safarian, Alek // Australasian Biotechnology;Oct2011, Vol. 21 Issue 3, p47 

    At barely over 30 years old, the clinical trial outsourcing industry is young. Having grown from a standing start to a US$20+ billion market in a few short decades, it has seen a great deal of change over the years. This article reviews some of the key dynamics that have influenced the...

  • Biotechs Begin with the End in Mind. Henderson, Lisa // Applied Clinical Trials;Oct2011, Vol. 20 Issue 10, p10 

    No abstract available.

  • Companies Take the Outside Route for Clinical Trials. Gwynne, Peter // Drug Discovery & Development;Dec2002, Vol. 5 Issue 11, p71 

    Reports on the increase in the number of pharmacological clinical trials being outsourced by pharmaceutical and biotechnology companies. Reason behind the trend; Impact of the growth in outsourcing on the industry; Benefits provided by outsourcing to the industry. INSET: The Global Perspective...

  • Outsourcing Clinical Trials. Nicholas, Joanne // JNCI: Journal of the National Cancer Institute;7/18/2012, Vol. 104 Issue 14, p1043 

    The article reports on the outsourcing of clinical trials by biotechnology and pharmaceutical firms in 2012 due to increased costs of conducting research and the challenge of recruiting patients in the U.S. It states the growth in clinical trials in China as a result of its medical...

  • PRA International.  // Applied Clinical Trials;Dec2010, Vol. 19 Issue 12, p126 

    The article presents the corporate profile of PRA International, a clinical research organization which provides services in clinical development based in Raleigh, North Carolina. The company supports over 3,000 clinical trials in 85 countries. Its therapeutic expertise, project experience, and...

  • PRA International.  // Applied Clinical Trials;Dec2005, Vol. 14 Issue 12, p156 

    The article presents information on PRA International Inc., one of the world's leading clinical development organizations. It is a full service clinical research organization that offers a broad array of services. The services provided by it cover the whole cycle of clinical development programs...

  • The quiet rise of the clinical contractor. Wadman, Meredith // Nature;5/4/2006, Vol. 441 Issue 7089, p22 

    The article focuses on PRA International, a major contract-research organization in the worldwide drug industry. Contractors manage an increasing proportion of clinical trials. Growth has been recorded in the total value of contract research in the drug industry. Global access to investigators...

  • The Middle East: Pharma's New Frontier: Room for growth in these markets. Kermani, Faiz // Contract Pharma;Nov/Dec2009, Vol. 11 Issue 9, p76 

    The article discusses the trends in the pharmaceutical market in the Middle East. It cites the regional value and potential of the Middle East pharmaceutical sector, as well as the presence of multinational pharmaceutical companies in the region. The rise of biotechnology and the interest for...

  • Steps to Functional Service Provider Success. Lucas, Kristin M. // Applied Clinical Trials;Aug2008, Vol. 17 Issue 8, p50 

    The article focuses on the outsourcing clinical trials that has became a standard practice in the biotech and pharmaceutical industries as companies attempt to make greater efficiencies while reducing costs, resources, and timelines. Moreover, it says that as industry's outsourcing experience...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics